Cited by

• A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases.

  Martínez C, Juarranz Y, Gutiérrez-Cañas I, Carrión M, Pérez-García S, Villanueva-Romero R, Castro D, Lamana A, Mellado M, González-Álvaro I, Gomariz RP. Martínez C, et al. Int J Mol Sci. 2019 Dec 20;21(1):65. doi: 10.3390/ijms21010065. Int J Mol Sci. 2019. PMID: 31861827 Free PMC article. Review.
• The effect of vasoactive intestinal polypeptide (VIP) on forskolin stimulated adenylate cyclase in the caudate-putamen of the rat.

  Moser A, Drescher S. Moser A, et al. Exp Brain Res. 1990;79(2):383-7. doi: 10.1007/BF00608248. Exp Brain Res. 1990. PMID: 2323384
• Predominant expression of type II vasoactive intestinal peptide receptors by human T lymphoblastoma cells: transduction of both Ca2+ and cyclic AMP signals.

  Xia M, Sreedharan SP, Goetzl EJ. Xia M, et al. J Clin Immunol. 1996 Jan;16(1):21-30. doi: 10.1007/BF01540969. J Clin Immunol. 1996. PMID: 8926282
• The presence of vasoactive intestinal polypeptide (VIP)-like-immunoreactive nerve fibres and VIP-receptors in the pineal gland of the Mongolian gerbil (Meriones unguiculatus). An immunohistochemical and receptor-autoradiographic study.

  Møller M, Mikkelsen JD, Fahrenkrug J, Korf HW. Møller M, et al. Cell Tissue Res. 1985;241(2):333-40. doi: 10.1007/BF00217178. Cell Tissue Res. 1985. PMID: 2992794
• VIP enhances both pre- and postsynaptic GABAergic transmission to hippocampal interneurones leading to increased excitatory synaptic transmission to CA1 pyramidal cells.

  Cunha-Reis D, Sebastião AM, Wirkner K, Illes P, Ribeiro JA. Cunha-Reis D, et al. Br J Pharmacol. 2004 Nov;143(6):733-44. doi: 10.1038/sj.bjp.0705989. Epub 2004 Oct 25. Br J Pharmacol. 2004. PMID: 15504757 Free PMC article.